Radiation Injury - Pipeline Review, H1 2018

  • ID: 4529335
  • Report
  • 46 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • FirstString Research Inc
  • PharmaIN Corp
  • Synedgen Inc
  • Windtree Therapeutics Inc
  • MORE
Radiation Injury - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Radiation Injury - Pipeline Review, H1 2018, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.

Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure causes local radiation injury.

Report Highlights:

This latest pipeline guide Radiation Injury - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Radiation Injury (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Injury (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiation Injury (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Injury (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiation Injury (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiation Injury (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiation Injury (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Injury (Toxicology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Injury (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Injury (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • FirstString Research Inc
  • PharmaIN Corp
  • Synedgen Inc
  • Windtree Therapeutics Inc
  • MORE
Introduction

Report Coverage

Radiation Injury - Overview

Radiation Injury - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Radiation Injury - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Radiation Injury - Companies Involved in Therapeutics Development

FirstString Research Inc

PharmaIN Corp

Synedgen Inc

Tonix Pharmaceuticals Holding Corp

Windtree Therapeutics Inc

Radiation Injury - Drug Profiles

Aerosurf - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-2E2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-2E5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Des-Asp Angiotensin 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DG-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSJ-0017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYGN-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Radiation Injury - Dormant Projects

Radiation Injury - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Table 1: Number of Products under Development for Radiation Injury, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Universities/Institutes, H1 2018

Table 4: Products under Development by Companies, H1 2018

Table 5: Products under Development by Universities/Institutes, H1 2018

Table 6: Number of Products by Stage and Target, H1 2018

Table 7: Number of Products by Stage and Mechanism of Action, H1 2018

Table 8: Number of Products by Stage and Route of Administration, H1 2018

Table 9: Number of Products by Stage and Molecule Type, H1 2018

Table 10: Radiation Injury - Pipeline by FirstString Research Inc, H1 2018

Table 11: Radiation Injury - Pipeline by PharmaIN Corp, H1 2018

Table 12: Radiation Injury - Pipeline by Synedgen Inc, H1 2018

Table 13: Radiation Injury - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018

Table 14: Radiation Injury - Pipeline by Windtree Therapeutics Inc, H1 2018

Table 15: Radiation Injury - Dormant Projects, H1 2018

Table 16: Radiation Injury - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Radiation Injury, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Targets, H1 2018

Figure 4: Number of Products by Stage and Targets, H1 2018

Figure 5: Number of Products by Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Routes of Administration, H1 2018

Figure 9: Number of Products by Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • FirstString Research Inc
  • PharmaIN Corp
  • Synedgen Inc
  • Tonix Pharmaceuticals Holding Corp
  • Windtree Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll